(Total Views: 306)
Posted On: 01/11/2021 11:57:29 AM
Post# of 63
Lypdiso is the brand name for MAT 9001, that is now in a second head to head trial vs. Vascepa, with topline results to be announced in 1Q 21. I expect such results to again show that MAT 9001 is far superior to Vascepra in lowering triglycerides, PCSK9, and various other lipid markers.
Also in the MTNB pipeline are (1) MAT 2203 (LNC version of amphotericin b), which is now in a Phase 2 trial for cryptococcal meningitis, fully funded and sponsored by the NIH, and (2) MAT 2205 (LNC version of amikacin), which has funding for research from the Cystic Fibrosis Foundation.
Of course, the LNC platform can potentially make many more effective, but highly toxic, drugs, safe and effective, which is why five big pharmaceutical companies are now in collaborations with MTNB to encochleate their drugs.
Also in the MTNB pipeline are (1) MAT 2203 (LNC version of amphotericin b), which is now in a Phase 2 trial for cryptococcal meningitis, fully funded and sponsored by the NIH, and (2) MAT 2205 (LNC version of amikacin), which has funding for research from the Cystic Fibrosis Foundation.
Of course, the LNC platform can potentially make many more effective, but highly toxic, drugs, safe and effective, which is why five big pharmaceutical companies are now in collaborations with MTNB to encochleate their drugs.
(0)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
Scroll down for more posts ▼
